FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Tate Michael Truett				2. Issuer Name and Astera Labs,				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
(Last) C/O ASTERA 2901 TASMA	3. Date of Earliest 12/02/2024	Transac	tion (N	Month/Day/Ye	Officer (give title Other (specify below) Chief Financial Officer								
(Street) SANTA CLARA CA 95054				4. If Amendment, D	ate of C	Origina	al Filed (Montl	6. Indiv Line)	<u>, </u>				
(City)	(State)	(Zip											
Date			2. Transaction	2A. Deemed Execution Date,	3. Transaction Code (Instr. 8)		4. Securities Disposed Of	ed (A) or		5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership	
					Code V		Amount (A) or (D) Price		Price		Following Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock			12/02/2024		S ⁽¹⁾		24,077	D	\$101.6	522(2)	1,738,811	I	By Tate Trust ⁽³⁾
Common Stock			12/02/2024		S ⁽¹⁾		55,003	D	\$102.5	867(4)	1,683,808	I	By Tate Trust ⁽³⁾
Common Stock	[12/02/2024		S ⁽¹⁾		84,220	D	\$103.4	899(5)	1,599,588	I	By Tate Trust ⁽³⁾
Common Stock			12/02/2024		S ⁽¹⁾		3,700	D	\$104.4	404(6)	1,595,888	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		1,185	D	\$105.8	011 ⁽⁷⁾	1,594,703	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		1,600	D	\$107.0)75 ⁽⁸⁾	1,593,103	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		1,180	D	\$108.1	583 ⁽⁹⁾	1,591,923	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		4,575	D	\$109.58	332(10)	1,587,348	I	By Tate Trust ⁽³⁾
Common Stock	[12/03/2024		S ⁽¹⁾		21,670	D	\$110.52	248(11)	1,565,678	I	By Tate Trust ⁽³⁾
Common Stock	[12/03/2024		S ⁽¹⁾		19,793	D	\$111.31	158(12)	1,545,885	I	By Tate Trust ⁽³⁾
Common Stock	[12/03/2024		S ⁽¹⁾		27,905	D	\$112.53	336(13)	1,517,980	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		18,489	D	\$113.54	127(14)	1,499,491	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		19,804	D	\$114.53	382(15)	1,479,687	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		25,978	D	\$115.71	146 ⁽¹⁶⁾	1,453,709	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		23,222	D	\$116.45	583(17)	1,430,487	I	By Tate Trust ⁽³⁾
Common Stock			12/03/2024		S ⁽¹⁾		1,599	D	\$117.	1(18)	1,428,888	I	By Tate Trust ⁽³⁾

1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	Exe	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)				quired (A) or (Instr. 3, 4 and 5)			5. Amo Securi Benefi Owned Follow	ities icially d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of I Be	Nature Indirect eneficial vnership estr. 4)	
				Code			e V	Amount (A		A) or D)) or Price				ted action(s) 3 and 4)				
Common	Stock									28	86,424	D							
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				Expiration	Exercisable and on Date Day/Year)		Am Sec Und Der Sec 3 an	Title and nount of curities detrying rivative curity (Instr. and 4) Amount or Number of Shares		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	ip o	11. Nature of Indirect Seneficial Ownership Instr. 4)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Explanation of Responses:

- 1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$101.0500 to \$102.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. These shares are owned directly by Michael T Tate and Jeanne Larue Tate as Trustees of the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$102.0500 to \$103.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$103.0500 to \$104.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$104.0500 to \$104.9100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$105.5800 to \$106.4500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$106.7900 to \$107.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$107.8600 to \$108.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$108.9500 to \$109.9200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$109.9700 to \$110.9650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 12. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$110.9700 to \$111.9500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 13. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$112.0300 to \$113.0200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 14. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$113.0300 to \$114.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 15. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$114.0500 to \$115.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 16. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$115.0500 to \$116.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 17. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$116.0500 to \$117.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 18. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$117.0500 to \$117.1700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Philip Mazzara, Attorneyin-Fact 12/04/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.